Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study
verteporfin
+ conventional surgery
Brain Diseases+38
+ Central Nervous System Diseases
+ Cerebral Ventricle Neoplasms
Treatment Study
Summary
Study start date: May 1, 1994
Actual date on which the first participant was enrolled.OBJECTIVES: Determine the maximum tolerated dose of benzoporphyrin monoacid ring A in patients with refractory brain tumors undergoing cavitary photoillumination photodynamic therapy. Determine the effect of this regimen on neurotoxicity, clinical state, imaging changes, and survival of these patients. OUTLINE: This is a dose-escalation study. Patients are stratified according to tumor location (posterior fossa tumors vs all other brain tumors). Patients receive benzoporphyrin monoacid ring A (BPD-MA) IV preoperatively. Approximately 3 hours after BPD-MA administration, patients undergo craniotomy with photoillumination of the tumor. Patients with tumors greater than 2 cm in diameter also undergo gross tumor resection. Cohorts of 3-6 patients receive escalating doses of BPD-MA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose immediately preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Three additional patients are treated at the MTD. Patients are followed at 4 and 6 weeks, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter. PROJECTED ACCRUAL: A minimum of 24 patients will be accrued for this study within 3 years.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.24 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 3 to 70 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
DISEASE CHARACTERISTICS: Diagnosis of supratentorial or infratentorial brain tumor Localized, non-disseminated Primary tumor or solitary metastasis Recurrent or progressive Unresectable Negative CSF Must have failed standard therapy including radiotherapy Measurable disease as evidenced by CT scan or MRI Single or multiple masses accessible to light administration PATIENT CHARACTERISTICS: Age: 3 to 70 Performance status: Not specified Life expectancy: At least 2 months Hematopoietic: Absolute neutrophil count at least 1,000/mm3 May transfuse platelets Hepatic: PT and PTT normal Renal: Not specified Other: Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior brachytherapy Surgery: See Disease Characteristics Other: No other concurrent antitumor therapy
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
Medical College of Wisconsin Cancer Center
Milwaukee, United StatesOpen Medical College of Wisconsin Cancer Center in Google MapsMidwest Children's Cancer Center at Children's Hospital of Wisconsin
Milwaukee, United States